-
Mashup Score: 1ESC 23: ARAMIS: Anakinra versus Placebo in Acute Myocarditis - 7 month(s) ago
ESC 23 – We are joined onsite by Dr Mathieu Kerneis (Pitie Salpetriere APHP University Hospital, FR) and Dr Gilles Montalescot to discuss the findings from the ARAMIS trial. ARAMIS was the
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 6AUA 2023: Treatment Duration and Long-term Safety and Tolerability With Darolutamide in nmCRPC: ARAMIS Rollover Study - 11 month(s) ago
AUA 2023 ARAMIS Rollover Study, treatment duration and long-term safety and tolerability with darolutamide in nmCRPC, patients with nmCRPC, darolutamide in nmCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the European urology publication Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Darolutamide is one of three agents that’s been assessed in this space,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the European urology publication Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Darolutamide is one of three agents that’s been assessed in this space,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 6ASCO GU 2023: Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study - 1 year(s) ago
ASCO GU 2023 ARAMIS Rollover Study, safety and tolerability of darolutamide, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide treatment in the ARAMIS Rollover Study,
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Comprehensive insight on darolutamide therapy in nonmetastatic CRPC, supported by clinical data from the ARAMIS trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2ASCO 2022: Progression Patterns by Types of Metastatic Spread, PSA, and Clinical Symptoms: Post-Hoc Analyses of ARAMIS - 2 year(s) ago
ASCO 2022 ARAMIS trial, progression patterns of patients with non-metastatic castration resistant prostate cancer (nmCRPC) in the ARAMIS trial.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
ASCO GU 2022 the safety and the efficacy of darolutamide in nmCRPC is consistent across subgroups of patients defined based on comorbidity and concomitant use of medication, the effects of comorbidities and concomitant medications among patients on the ARAMIS trial
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke - 2 year(s) ago
Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
🫀NEW #ESCCongress #LBCT Interview 💫Dr @mathieukerneis and Dr Gilles Montalescot discuss findings from the #ARAMIS trial. 📽️👉 https://t.co/zg9bByyrEO 📊Results showed that #anakinra was safe but did not reduce the complications of acute myocarditis. #ESC2023 #CardioTwitter https://t.co/9AGMF59hbX